Gehlert D R
Lilly Research Laboratories, Neuroscience Division, Eli Lilly and Company, Lilly Corporate Center, Mail Code 0510, Indianapolis, IN 46285, USA.
Neuropeptides. 2004 Aug;38(4):135-40. doi: 10.1016/j.npep.2004.07.002.
Neuropeptide Y (NPY) was first reported as an abundant peptide in brain tissue in 1982. Shortly thereafter, NPY was found to be a member of a peptide family consisting of the endocrine peptides pancreatic polypeptide (PP) and peptide YY (PYY). These peptides exert most of their biological effects through five G-protein coupled receptors termed Y1, Y2, Y4, Y5 and y6 that mediate either inhibition adenylate cyclase or increases in intracellular calcium. Since the discovery of NPY, a robust a body of literature has developed around the potential functions of this peptide. While initial findings identified NPY is an important contributor to the regulation of feeding, body weight and blood pressure, more recent work as revealed more subtle functions of this peptide and its potential role in affective disorders, bone formation and cravings. The accompanying twelve reviews detail important developments in our understanding of the functional role of NPY.
神经肽Y（NPY）于1982年首次被报道为脑组织中一种丰富的肽。此后不久，NPY被发现是由内分泌肽胰多肽（PP）和肽YY（PYY）组成的肽家族的一员。这些肽通过五种G蛋白偶联受体发挥其大部分生物学效应，这些受体被称为Y1、Y2、Y4、Y5和Y6，它们介导腺苷酸环化酶的抑制或细胞内钙的增加。自NPY被发现以来，围绕这种肽的潜在功能已经形成了大量的文献。虽然最初的研究结果表明NPY是调节进食、体重和血压的重要因素，但最近的研究揭示了这种肽更微妙的功能及其在情感障碍、骨形成和渴望中的潜在作用。随附的十二篇综述详细介绍了我们对NPY功能作用理解的重要进展。
